NICE recommends kidney cancer drug “likely to be less effective” than current treatments after price deal
Sign Up to like & getrecommendations! Published in 2018 at "British Medical Journal"
DOI: 10.1136/bmj.k752
Abstract: The National Institute for Health and Care Excellence (NICE) has recommended tivozanib as an option for treating adults with previously untreated advanced renal cell carcinoma, after the manufacturer agreed a discount to make the cost… read more here.
Keywords: less effective; recommends kidney; likely less; nice recommends ... See more keywords